EPO Patent Application EP4522154A1: BCL-XL/BCL-2 Degraders

The European Patent Office has published patent application EP4522154A1 by Kymera Therapeutics, Inc. The application details BCL-XL/BCL-2 degraders and their uses. This publication is part of the standard patent application process.

Novel Psilocin Prodrug Compounds and Synthesis Methods Patent

The European Patent Office has published patent application EP4522167A1 concerning novel psilocin prodrug compounds and their synthesis methods. The application was filed by Mydecine Innovations Group Inc. and lists Denton W. Hoyer and Robert F. Roscow as inventors. The publication date is March 18, 2026.

EPO Patent: Selective Regulatory Gene System for Genetically Modified Immune Cell Therapy

The European Patent Office has published patent application EP4502162A1 concerning a Selective Regulatory Gene (SRG) System for Genetically Modified Immune Cell Therapy. The patent application lists Jichi Medical University and Takara Bio Inc. as applicants.

EPO Patent Publication EP4501364A1: Hydrogel

The European Patent Office published patent application EP4501364A1 on March 18, 2026, related to hydrogel technology. The applicant is Sekisui Kasei Co., Ltd. This publication is part of the standard patent application process.

EPO Patent Publication EP4504168A1 for Cannabinoid Compositions

The European Patent Office published patent application EP4504168A1 for cannabinoid-containing compositions on March 18, 2026. The patent was applied for by Buzzelet Development And Technologies Ltd.

Process for Preparation of Belumosudil Mesylate and Crystalline Form

The European Patent Office has published patent application EP4499600A1 concerning a process for the preparation of Belumosudil Mesylate and its crystalline form. The application was published on March 18, 2026, by Alivus Life Sciences Limited.

EPO Patent EP4499622A1: Propanamido Derivatives by Lunella Biotech

The European Patent Office has published patent application EP4499622A1 for '2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES' by Lunella Biotech, Inc. The patent application details novel chemical compounds and their potential applications.

EPO Patent Application: Mulberry Extract for Ulcerative Colitis

The European Patent Office has published a patent application (EP4501343A1) for a drug utilizing mulberry extract to treat ulcerative colitis. The application lists Beijing Wehand-Bio Pharmaceutical Co., Ltd and Guangxi Wehand-Bio Pharmaceutical Co., Ltd as applicants.

NLRP3 Inflammasome Inhibitors Patent Application

The European Patent Office has published patent application EP4499646A1 concerning NLRP3 Inflammasome Inhibitors. The application was published on March 18, 2026, with Hangzhou Highlightll Pharmaceutical Co., Ltd. listed as the applicant.

EPO Patent Publication: PTK7-Binding Protein

The European Patent Office has published a patent application (EP4573129A1) for a PTK7-binding protein and its use, filed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. The publication date is March 18, 2026.